<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337739</url>
  </required_header>
  <id_info>
    <org_study_id>STU00027663</org_study_id>
    <nct_id>NCT01337739</nct_id>
  </id_info>
  <brief_title>Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery</brief_title>
  <official_title>Use of Dexmedetomidine for Deep Sedation in Patients Undergoing Outpatient Hysteroscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing deep sedation for outpatient procedures typically receive a combination
      of benzodiazepines, propofol, and opioids. Side effects of such anesthetics include
      respiratory depression, nausea and vomiting, and urinary retention, with resultant extended
      hospital stays and unanticipated admission. The use of dexmedetomidine for deep sedation may
      increase patient safety by maintaining respiratory drive, while providing sedation, hypnosis,
      and analgesia. Furthermore, patients may experience decreased pain, nausea, and time to
      discharge in the PACU, especially if dexmedetomidine decreases the requirement of other drugs
      such as opioids.

      The hypothesis of this study is administration of dexmedetomidine during deep sedation for
      ambulatory hysteroscopic surgery will result in a 50% reduction of intraoperative opioid
      compared to sedation with propofol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited up to 21 days prior to the day of surgery. Preoperatively: A full
      preoperative assessment will be completed. Preoperatively, patients will be instructed on the
      proper use of the verbal rating scale (VRS) for pain and nausea scores. Patients will be
      randomized by a computer-generated scheme to receive prepared infusions containing either
      dexmedetomidine (4grams per milliliter or propofol (10 milligrams per milliliter)
      intraoperatively. The study drug infusions will be prepared by study personnel who are not
      involved in the assessments. Patients, medical personnel other than the anesthesiologist, and
      outcome assessors will be blinded to treatment allocation. Only the anesthesiologist
      administering the treatment infusion and medications intraoperatively will be aware of group
      allocation.

      Intraoperatively: A standardized intraoperative anesthetic plan will be utilized by the
      anesthesia personnel.All patients will receive premedication with midazolam 2 milligrams
      intravenous bolus and ketorolac 30 milligrams via the intravenous catheter.

      Intraoperative monitoring will include standard monitoring which includes noninvasive blood
      pressure, electrocardiography, pulse oximetry, and capnography. In addition transcutaneous
      CO2 will be monitored using the Tosca monitor.(Radiometer, Basel, Austria).

      The study drug infusion will be started as either dexmedetomidine (1gram per kilogram over 10
      min as a loading dose, followed by a maintenance infusion 0.2 to 1.5 grams per kilogram or
      propofol (started at 75gram per kilogram per minute and ranging from 12.5 to 125 gram per
      kilogram per minute titrated to maintain the Observer's Assessment of Alertness/Sedation
      Scale (OAA/SS) between 0-1. Intraoperative fluids will be restricted to 500 milliliter +
      100mililiterml of Lactated Ringer's solution. At the onset of the procedure, the
      anesthesiologist will administer 0.7gram/kilogram bolus of fentanyl intravenous, followed by
      additional 25-50gram boluses for any patient movement to surgical stimulus. All patients will
      receive ondansetron 4 milligram IV 15-20 minutes prior to the end of surgery. Patients will
      receive glycopyrrolate 0.2 mg IV if HR decreases below 50 bpm.

      Postoperatively:

      In the recovery room, VRS for pain will be assessed upon admission and at 30 minute intervals
      thereafter. Analgesics will be administered according to the severity of the pain and degree
      of alertness.Vomiting and retching episodes.will be assessed at 30 minute intervals using a
      VRS, and patients with scores greater than 4 or those who request antiemetic treatment will
      be treated with metoclopramide 10 mg IV.

      Recovery from anesthesia and return of psychomotor ability will be assessed using the
      Modified Post Anesthesia Discharge Scoring System (MPADSS). A score of 8 or greater will
      indicate discharge readiness. Discharge readiness requires that a patient be awake and alert
      with stable vital signs, able to ambulate without assistance, and free of side effects. 24
      hours after discharge.

      Times from end of surgery to oral intake and readiness for discharge, , and all adverse
      events and medications administered will be recorded. These data will be recorded by research
      staff blinded to the study group assignments. Subjects will be contacted by telephone 24
      hours after surgery to obtain post-discharge data, including a repeat QoR-40 assessment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study drug delayed time of discharge which is clinically impracticable.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Will be the Difference in Intraoperative Opioid (Fentanyl) Administration Between Patients Receiving Dexmedetomidine and Those Receiving Propofol.</measure>
    <time_frame>Interoperative period</time_frame>
    <description>The primary outcome will be the difference in intraoperative opioid (fentanyl) administration between patients receiving dexmedetomidine and those receiving propofol. As described by mean and standard deviation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge</measure>
    <time_frame>24 Hours</time_frame>
    <description>Time to discharge from the Post Anesthesia Care Unit or home or to hospital room.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continuous infusion of placebo during operative procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of Dexmedetomidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo administration (.9 normal saline sterile)</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator</intervention_name>
    <description>Administration of Dexmedetomidine</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA I-II

          -  Age: 18-64 years

          -  Female

          -  Surgery: Gynecologic hysteroscopy

          -  Language: English speaking

          -  Consent: Obtained

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  Significant arrhythmia or high degree atrioventricular nodal block

          -  Significant hepatic or renal dysfunction

          -  Chronic use or addiction to opiates or sedatives

          -  History of heavy alcohol usage (&gt;4 drinks/day)

          -  Psychiatric or emotional disorder

          -  Chronic use of Î±2-agonists

          -  Patients with OSA or BMI greater than 30

          -  Allergy to study drug or anesthetic medications utilized in the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shireen Ahmad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prentice Womens Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bhananker SM, Posner KL, Cheney FW, Caplan RA, Lee LA, Domino KB. Injury and liability associated with monitored anesthesia care: a closed claims analysis. Anesthesiology. 2006 Feb;104(2):228-34.</citation>
    <PMID>16436839</PMID>
  </reference>
  <reference>
    <citation>Panzer O, Moitra V, Sladen RN. Pharmacology of sedative-analgesic agents: dexmedetomidine, remifentanil, ketamine, volatile anesthetics, and the role of peripheral mu antagonists. Crit Care Clin. 2009 Jul;25(3):451-69, vii. doi: 10.1016/j.ccc.2009.04.004.</citation>
    <PMID>19576524</PMID>
  </reference>
  <reference>
    <citation>Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs. 2000 Feb;59(2):263-8; discussion 269-70.</citation>
    <PMID>10730549</PMID>
  </reference>
  <reference>
    <citation>Kaygusuz K, Gokce G, Gursoy S, Ayan S, Mimaroglu C, Gultekin Y. A comparison of sedation with dexmedetomidine or propofol during shockwave lithotripsy: a randomized controlled trial. Anesth Analg. 2008 Jan;106(1):114-9, table of contents. doi: 10.1213/01.ane.0000296453.75494.64.</citation>
    <PMID>18165564</PMID>
  </reference>
  <reference>
    <citation>Taghinia AH, Shapiro FE, Slavin SA. Dexmedetomidine in aesthetic facial surgery: improving anesthetic safety and efficacy. Plast Reconstr Surg. 2008 Jan;121(1):269-76. doi: 10.1097/01.prs.0000293867.05857.90.</citation>
    <PMID>18176230</PMID>
  </reference>
  <reference>
    <citation>Koroglu A, Teksan H, Sagir O, Yucel A, Toprak HI, Ersoy OM. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Anesth Analg. 2006 Jul;103(1):63-7, table of contents.</citation>
    <PMID>16790627</PMID>
  </reference>
  <reference>
    <citation>Bergese SD, Khabiri B, Roberts WD, Howie MB, McSweeney TD, Gerhardt MA. Dexmedetomidine for conscious sedation in difficult awake fiberoptic intubation cases. J Clin Anesth. 2007 Mar;19(2):141-4. Erratum in: J Clin Anesth. 2007 Jun;19(4):323.</citation>
    <PMID>17379129</PMID>
  </reference>
  <reference>
    <citation>McCutcheon CA, Orme RM, Scott DA, Davies MJ, McGlade DP. A comparison of dexmedetomidine versus conventional therapy for sedation and hemodynamic control during carotid endarterectomy performed under regional anesthesia. Anesth Analg. 2006 Mar;102(3):668-75.</citation>
    <PMID>16492813</PMID>
  </reference>
  <reference>
    <citation>Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg. 2002 Aug;95(2):461-6, table of contents.</citation>
    <PMID>12145072</PMID>
  </reference>
  <reference>
    <citation>Tufanogullari B, White PF, Peixoto MP, Kianpour D, Lacour T, Griffin J, Skrivanek G, Macaluso A, Shah M, Provost DA. Dexmedetomidine infusion during laparoscopic bariatric surgery: the effect on recovery outcome variables. Anesth Analg. 2008 Jun;106(6):1741-8. doi: 10.1213/ane.0b013e318172c47c.</citation>
    <PMID>18499604</PMID>
  </reference>
  <reference>
    <citation>Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB, Schwam EM, Siegel JL. Validity and reliability of the Observer's Assessment of Alertness/Sedation Scale: study with intravenous midazolam. J Clin Psychopharmacol. 1990 Aug;10(4):244-51.</citation>
    <PMID>2286697</PMID>
  </reference>
  <reference>
    <citation>Chung F. Discharge criteria--a new trend. Can J Anaesth. 1995 Nov;42(11):1056-8.</citation>
    <PMID>8590498</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <results_first_submitted>May 23, 2013</results_first_submitted>
  <results_first_submitted_qc>May 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2013</results_first_posted>
  <last_update_submitted>May 23, 2013</last_update_submitted>
  <last_update_submitted_qc>May 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Shireen Ahmad</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hysteroscopic Surgery</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Sedation</keyword>
  <keyword>Opioids</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were introduced to the study in a clinic setting and allowed to review the consent prior to their operative procedure.</recruitment_details>
      <pre_assignment_details>10 subjects were approached and all of the subjects agreed to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Comparator</title>
          <description>Continuous infusion of placebo during operative procedure</description>
        </group>
        <group group_id="P2">
          <title>Active Comparator</title>
          <description>Administration of Dexmedetomidine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 10 subjects participating were used in final analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo Comparator</title>
          <description>Continuous infusion of placebo during operative procedure</description>
        </group>
        <group group_id="B2">
          <title>Active Comparator</title>
          <description>Administration of Dexmedetomidine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="8.4"/>
                    <measurement group_id="B2" value="41.5" spread="7.43"/>
                    <measurement group_id="B3" value="42.8" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Will be the Difference in Intraoperative Opioid (Fentanyl) Administration Between Patients Receiving Dexmedetomidine and Those Receiving Propofol.</title>
        <description>The primary outcome will be the difference in intraoperative opioid (fentanyl) administration between patients receiving dexmedetomidine and those receiving propofol. As described by mean and standard deviation.</description>
        <time_frame>Interoperative period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator</title>
            <description>Continuous infusion of placebo during operative procedure</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator</title>
            <description>Administration of Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Will be the Difference in Intraoperative Opioid (Fentanyl) Administration Between Patients Receiving Dexmedetomidine and Those Receiving Propofol.</title>
          <description>The primary outcome will be the difference in intraoperative opioid (fentanyl) administration between patients receiving dexmedetomidine and those receiving propofol. As described by mean and standard deviation.</description>
          <units>Total Morphine Equivalents mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" spread="3.5"/>
                    <measurement group_id="O2" value="11.58" spread="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge</title>
        <description>Time to discharge from the Post Anesthesia Care Unit or home or to hospital room.</description>
        <time_frame>24 Hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Comparator</title>
            <description>Continuous infusion of placebo during operative procedure</description>
          </group>
          <group group_id="O2">
            <title>Active Comparator</title>
            <description>Administration of Dexmedetomidine</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge</title>
          <description>Time to discharge from the Post Anesthesia Care Unit or home or to hospital room.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.16" spread="30"/>
                    <measurement group_id="O2" value="115" spread="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo Comparator</title>
          <description>Continuous infusion of placebo during operative procedure</description>
        </group>
        <group group_id="E2">
          <title>Active Comparator</title>
          <description>Administration of Dexmedetomidine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of the study due to increased discharge time from the post anesthesia care unit with subjects receiving dexmedetomidine. The delay was consistent among the group.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Fitzgerald</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-472-3539</phone>
      <email>p-fitzgerald2@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

